8-K: Sage Therapeutics Reports Q2 2024 Results: ZURZUVAE Sales Up, Pipeline Progress Mixed

Sage Therapeutics announced its second quarter 2024 financial results, highlighting growth in ZURZUVAE sales and mixed progress in its pipeline development.

Summary

• Sage Therapeutics reported $7.4 million in collaboration revenue from ZURZUVAE in Q2 2024, a 19% increase from Q1 2024.
• Over 1,400 ZURZUVAE prescriptions were shipped and delivered in Q2 2024, nearly double the amount from Q1.
• The company's cash, cash equivalents, and marketable securities totaled $647 million as of June 30, 2024.
• Topline data for Dalzanemdor (SAGE-718) from the LIGHTWAVE and DIMENSION studies are expected in late 2024.
• The primary endpoint for the DIMENSION study was adjusted from the HD-CAB composite to the Symbol Digit Modalities Test (SDMT).
• SAGE-324 did not meet its primary endpoint in the KINETIC 2 study for essential tremor, leading to the termination of the program.
• Net loss for the quarter was $102.9 million, compared to $160.3 million for the same period in 2023.
• The company anticipates its current cash position will support operations into 2026.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While ZURZUVAE is showing positive early commercial performance, the failure of the SAGE-324 program and the net loss temper the overall outlook. The company's cash position is a positive, but the risks associated with drug development remain.

Positives

• ZURZUVAE is showing strong early commercial launch performance with a 19% increase in collaboration revenue from the previous quarter.
• The number of ZURZUVAE prescriptions shipped and delivered nearly doubled from the first quarter, indicating growing demand.
• The company has a solid cash position of $647 million, providing a runway into 2026.
• The majority of commercially insured patients using the ZURZUVAE savings card paid no copay.
• The company is making progress with payor coverage, with approximately 80% of commercial lives covered for PPD.
• Research and development expenses decreased due to the Q3 2023 restructuring.

Negatives

• The SAGE-324 program for essential tremor was terminated due to the KINETIC 2 study not meeting its primary endpoint.
• Net revenue from sales of ZULRESSO decreased to $0.6 million in Q2 2024, compared to $2.5 million in the same period of 2023.
• The company experienced a net loss of $102.9 million for the quarter.
• Wholesalers bringing down initial inventory levels impacted ZURZUVAE revenue in the second quarter of 2024.
• The company does not anticipate receiving any milestone payments from collaborations in the remainder of 2024.

Risks

• The commercial success of ZURZUVAE is not guaranteed and may not meet expectations.
• Clinical trials for Dalzanemdor may not be successful, impacting the company's pipeline.
• The company may face challenges in securing broad and equitable access to ZURZUVAE.
• The company's cash runway is dependent on anticipated funding from collaborations and estimated revenues.
• The company may encounter unexpected hurdles in the development and manufacture of its product candidates.
• The company may not be successful in gaining regulatory approval for products beyond ZURZUVAE and ZULRESSO.

Future Outlook

Sage anticipates its current cash position will support operations into 2026, with operating expenses expected to decrease in 2024 relative to 2023. The company expects ZULRESSO revenues to continue to decrease over time as ZURZUVAE becomes more established.

Management Comments

• We are pleased with the strength of ZURZUVAEs early commercial launch performance and its positive, real-world impact on women suffering from PPD, said Barry Greene, Chief Executive Officer at Sage Therapeutics.
• We believe ZURZUVAE is well-positioned to become the first line therapy and standard of care for women with PPD.
• While we are deeply disappointed by the results from the KINETIC 2 study and for the essential tremor community, we remain focused on progressing our pipeline and look forward to additional clinical data readouts expected in late 2024.

Industry Context

This announcement reflects the ongoing challenges and opportunities in the biopharmaceutical industry, particularly in the development and commercialization of treatments for neurological and psychiatric disorders. The mixed results highlight the risks associated with drug development and the importance of a diversified pipeline. The success of ZURZUVAE's launch is a positive sign for the company, but the failure of SAGE-324 underscores the high failure rate in clinical trials.

Comparison to Industry Standards

• The 19% quarter-over-quarter growth in ZURZUVAE revenue is a positive sign, but it is still early in the launch phase, and it is difficult to compare to established products.
• The termination of the SAGE-324 program is not uncommon in the pharmaceutical industry, where many clinical trials fail to meet their endpoints.
• The company's cash position of $647 million is relatively strong compared to other biotech companies of similar size, providing a runway into 2026.
• The adjustment of the primary endpoint in the DIMENSION study is a strategic move that is not unusual in clinical trials, but it introduces uncertainty about the study's outcome.
• The decrease in R&D expenses is a result of the restructuring, which is a common cost-cutting measure in the biotech industry.

Stakeholder Impact

• Shareholders may be concerned about the termination of the SAGE-324 program and the net loss, but encouraged by the ZURZUVAE launch.
• Employees may be affected by the restructuring and the termination of the SAGE-324 program.
• Patients with PPD may benefit from the availability of ZURZUVAE.
• Healthcare providers will have a new treatment option for PPD with ZURZUVAE.
• Payors will need to make coverage decisions for ZURZUVAE.

Next Steps

• Sage will continue the commercialization of ZURZUVAE for the treatment of women with PPD.
• The company will present analyses of real-world evidence for ZURZUVAE, including health economics and patient-reported outcomes.
• Topline data from the LIGHTWAVE and DIMENSION studies for Dalzanemdor are expected in late 2024.
• Sage will present additional analyses of data from the clinical development program for Dalzanemdor.
• The company will evaluate next steps, if any, for other potential indications for SAGE-324.

Key Dates

Keywords

ZURZUVAE, zuranolone, postpartum depression, PPD, Dalzanemdor, SAGE-718, Alzheimers Disease, Huntingtons Disease, SAGE-324, essential tremor, clinical trials, biopharmaceutical, revenue, financial results